Nanobiotix S.A.
ENXTPANANO cost to borrow surges to 20.0%, up 128% in one week as short-squeeze signals intensify.
Snapshot as of 4 Oct 2026
Nanobiotix enters September with a subdued but slightly accelerating slide — down 6.3% on the week to €33.50 — as the company heads toward a September 18 earnings event with a lending market that has just shifted…
NANO arrives at its June 5 earnings event on a sharp divergence — up 18% over the past month, down 8% across the past week, and closing yesterday at €31.24 after a 3.7% single-day bounce. That tug-of-war between the…
Nanobiotix heads into its May 22 results carrying a sharp contradiction: clinical data strong enough to impress oncologists, yet a stock that just shed 10% in a single session. The immediate catalyst is a striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NANO — free to start on ORTEX.
Sign up for free →Open NANO on ORTEX